
The AAAAI Foundation and Phil and Barbara Lieberman and Friends Lecture: Investing Together in Our Future



Phil Lieberman is a Clinical Professor of Pediatrics and Internal Medicine in the Allergy/Immunology division of the University Of Tennessee College Of Medicine in Memphis TN.

He is a graduate of the University Of Tennessee College Of Medicine and did his residency in Internal Medicine at this institution and completed his Allery-Immunology Fellowship at Northwestern University Medical school.

Upon completion of his fellowship he returned to the University of Tennessee to found the Allergy-Immunology

Division in the Department of Medicine. He is a past president of the AAAAI.

2017 marks the 3rd year of the AAAAI Foundation and Phil and Barbara Lieberman and Friends Lecture: Investing Together in Our Future. It will be presented in Symposium Session 3302: Anaphylaxis Old and New on Sunday, March 5, 2017: 10:45 to 12:00 pm, GWCC, Thomas B. Murphy Ballroom 2.

The AAAAI Foundation and Phil and Barbara Lieberman and Friends Lecture: Investing Together in Our Future – Antonella Cianferoni, MD PhD FAAAAI



Dr Cianferoni is an ABAI certified, practicing pediatric allergist with a special clinical and research interest in food allergy and eosinophilic esophagitis with extensive training in molecular biology and clinical studies.

Currently she splits her time evenly between clinical practice and research activities. Dr Cianferoni has graduated from the medical School University of Florence, Italy, where she also obtained her PhD in Pediatric Immunology. She has completed a residency school in Pediatrics at the A Meyer Hospital, University of Florence, and one at the Children's Hospital of Philadelphia. She has also done a research fellowship at John's Hopkins Allergy and Asthma Center

and a Clinical Allergy and Immunology Fellowship at the Boston's Children's Hospital.

Dr Cianferoni has clinically characterized several classical allergic diseases such as anaphylaxis, food allergy, hymenoptera venom hypersensitivity, atopic dermatitis, asthma. She has studied extensively anaphylactic reaction in children and adults, and outcome in food challenges in children. As post-doctoral fellow at the Hopkins Allergy and Asthma's center first and then Children's Hospital in Boston, she worked on transcriptional regulation of IL-4 and IL-2.

The results of her research were published in Blood and JACI. In the past several years, after joining the Allergy and Immunology Faculty in Department of Pediatrics at University of Pennsylvania, Perelman Medical School at The Children's Hospital of Philadelphia in 2007, she has started her laboratory that has focused on understanding how iNKT cell can contribute to food allergy pathogenesis including EoE (Jyonouchi et al JACI 2011, Jyonouchi et al Clinical Experimental allergy) and now has expanded her research to understand the role of other regulatory cells such as Treg in EoE, FPIES and IgE mediated milk allergy.

She contributed to the recent identification of TSLP, EMSY and CAPN14 as a genetic risk factor by Genome Wide Association Studies (Rothenberg M, Spergel JM et al Nature Genetics 2010, Sleiman P et al Nature Communications 2014), and to the characterization of TSLP and basophils in Eosinophilic esophagitis pathogenesis (Siracusa et al Nature 2011, Noti et al Nature Medicine 2013, Siracusa et la Immunity 2014). She is currently studying risk genetic risk factors for development of specific subtype of EoE. Her research has been funded by NIH, AAAAI/APFED 2015 HOPE/ARTrust.

In the past several years she also become more involved in clinical studies and currently she is the PI in the first in the world study for evaluation of Epicutaneous immunotherapy for milk desensitization in children with milk induced EoE (SMILEE, DBV) and I am a subinvestigator in many other clinical trials for oral and epicutaneous desensitization (VIPES-DBV, MILES-DBV, ARC-Alloimune, Multifood Xolair). She is Codirector of the FARE center at the Children's Hospital of Philadelphia as well as the director of the T cell core for the CEGIR study in EoE Finally Dr Cianferoni is in the leadership of the AAAAI as she is the current BCI secretary, and she is on the board of the interest group for Eosinophilic Esophagitis for the EAACI.